-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anetumab Ravtansine in Metastatic Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anetumab Ravtansine in Metastatic Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anetumab Ravtansine in Metastatic Pancreatic Cancer Drug Details: Anetumab ravtansine...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anetumab Ravtansine in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anetumab Ravtansine in Endometrial Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anetumab Ravtansine in Endometrial Cancer Drug Details: Anetumab ravtansine (BAY 94-9343)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anetumab Ravtansine in Uterine Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anetumab Ravtansine in Uterine Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anetumab Ravtansine in Uterine Cancer Drug Details: Anetumab ravtansine (BAY 94-9343)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anetumab Ravtansine in Fallopian Tube Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anetumab Ravtansine in Fallopian Tube Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anetumab Ravtansine in Fallopian Tube Cancer Drug Details: Anetumab ravtansine...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anetumab Ravtansine in Gastroesophageal (GE) Junction Carcinomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anetumab Ravtansine in Gastroesophageal (GE) Junction Carcinomas report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anetumab Ravtansine in Gastroesophageal (GE) Junction Carcinomas Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anetumab Ravtansine in Epithelial Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anetumab Ravtansine in Epithelial Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anetumab Ravtansine in Epithelial Ovarian Cancer Drug Details: Anetumab ravtansine...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anetumab Ravtansine in Peritoneal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anetumab Ravtansine in Peritoneal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anetumab Ravtansine in Peritoneal Cancer Drug Details: Anetumab ravtansine (BAY 94-9343)...
-
Company Insights
Kingfisher – Digital Transformation Strategies
Kingfisher Digital Transformation Strategies Overview Kingfisher has been focusing on using artificial intelligence, cloud-based mobile applications, big data, and augmented reality to digitally transform its operations. The annual ICT spending of Kingfisher was estimated at $369.9 million for 2023. A major share of this spending is earmarked for acquiring software, hardware, and ICT services from vendors. Kingfisher sells home improvement products and offers home improvement services to consumers and trade professionals in eight European countries. It operates under the B&Q,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Mirvetuximab Soravtansine in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mirvetuximab Soravtansine in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mirvetuximab Soravtansine in Triple-Negative Breast Cancer (TNBC) Drug Details:...
-
Sector Analysis
China Source Tourism Insight by Domestic and Outbound Tourism, Key Destinations and Tourist Profiles, 2024 Update
Explore thorough market trends and insights from the ‘China Source Tourism’ report: Get an in-depth analysis of traveler flows and spending patterns to understand the market better. The report looks at tourist profiles and summarizes the key reasons that they travel. Garner exhaustive data on the main and developing destination markets across regions. Stay up to date with current and future opportunities for tourism businesses seeking to tap into the China outbound travel market. Assess the impact of COVID-19 on domestic...